Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS.
暂无分享,去创建一个
Dirk Koczan | Michael Hecker | M. Hecker | H. Thiesen | U. Zettl | D. Koczan | R. Goertsches | P. Serrano-Fernández | Hans-Juergen Thiesen | Uwe K Zettl | Steffen Moeller | Pablo Serrano-Fernandez | Robert H Goertsches | Steffen Moeller
[1] J. Sepulcre,et al. A Network Analysis of the Human T-Cell Activation Gene Network Identifies Jagged1 as a Therapeutic Target for Autoimmune Diseases , 2007, PloS one.
[2] P. Rieckmann,et al. Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations , 2008, Journal of Neurology.
[3] M. Ramanathan,et al. Genomic effects of once-weekly, intramuscular interferon-β1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients , 2008, Journal of Neuroimmunology.
[4] Doron Lancet,et al. Novel definition files for human GeneChips based on GeneAnnot , 2007, BMC Bioinformatics.
[5] M. Ashburner,et al. Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.
[6] A. Bertolotto,et al. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1 , 2006, Multiple sclerosis.
[7] S. Hauser,et al. The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration , 2006, Neuron.
[8] Michael Hecker,et al. Integrative modeling of transcriptional regulation in response to antirheumatic therapy , 2009, BMC Bioinformatics.
[9] H. Salamon,et al. IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. , 2008, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[10] L. Staudt,et al. Complex immunomodulatory effects of interferon‐β in multiple sclerosis include the upregulation of T helper 1‐associated marker genes , 2001, Annals of neurology.
[11] V. Rivera,et al. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis , 2004, Journal of Neuroimmunology.
[12] P. Shannon,et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.
[13] B. Williams,et al. Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays , 1998 .
[14] Murali Ramanathan,et al. Genomic Effects of IFN-β in Multiple Sclerosis Patients 1 , 2003, The Journal of Immunology.
[15] J. Satoh,et al. Microarray analysis identifies interferon β-regulated genes in multiple sclerosis , 2003, Journal of Neuroimmunology.
[16] Kazumasa Yokoyama,et al. T cell gene expression profiling identifies distinct subgroups of Japanese multiple sclerosis patients , 2006, Journal of Neuroimmunology.
[17] M. Krumbholz,et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. , 2008, Brain : a journal of neurology.
[18] H. Weiner,et al. Systems biology approaches for the study of multiple sclerosis , 2008, Journal of cellular and molecular medicine.
[19] Graham R. Foster,et al. Interferons at age 50: past, current and future impact on biomedicine , 2007, Nature Reviews Drug Discovery.
[20] Tsippi Iny Stein,et al. GeneAnnot: comprehensive two-way linking between oligonucleotide array probesets and GeneCards genes. , 2004, Bioinformatics.
[21] A. Bertolotto,et al. Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis , 2005, Journal of Neuroimmunology.
[22] M. Hecker,et al. Monitoring of multiple sclerosis immunotherapy , 2008, Journal of Neurology.
[23] J. Satoh,et al. Aberrant transcriptional regulatory network in T cells of multiple sclerosis , 2007, Neuroscience Letters.
[24] A. Compston,et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.
[25] L. Staudt,et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. , 2003, Brain : a journal of neurology.
[26] G. Stark,et al. How cells respond to interferons. , 1998, Annual review of biochemistry.
[27] F. Sellebjerg,et al. Absence of MxA induction by interferon β in patients with MS reflects complete loss of bioactivity , 2009, Neurology.
[28] K. Vandenbroeck,et al. Pharmacogenomics of the response to IFN-beta in multiple sclerosis: ramifications from the first genome-wide screen. , 2008, Pharmacogenomics.
[29] X. Montalban,et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. , 2009, Brain : a journal of neurology.
[30] S. Akira,et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway , 2002, Nature Immunology.
[31] A. Lutterotti,et al. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients , 2006, Multiple sclerosis.
[32] J. Reischl,et al. Biological response genes after single dose administration of interferon β-1b to healthy male volunteers , 2008, Journal of Neuroimmunology.
[33] L. O’Neill,et al. Targeting signal transduction as a strategy to treat inflammatory diseases , 2006, Nature Reviews Drug Discovery.
[34] L. Steinman,et al. Systems biology and its application to the understanding of neurological diseases , 2009, Annals of neurology.
[35] B. Williams,et al. Functional classification of interferon‐stimulated genes identified using microarrays , 2001, Journal of leukocyte biology.
[36] H. Hartung,et al. Toward the development of rational therapies in multiple sclerosis: what is on the horizon? , 2007, Annals of neurology.
[37] B. Williams,et al. Novel interferon‐β‐induced gene expression in peripheral blood cells , 2007, Journal of leukocyte biology.
[38] Takashi Yamamura,et al. Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNβ-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNβ-related adverse effects in multiple sclerosis , 2006, BMC neurology.
[39] E. Coccia,et al. Gene expression profiles reveal homeostatic dynamics during interferon-β therapy in multiple sclerosis , 2007, Autoimmunity.
[40] A. Achiron,et al. Understanding Autoimmune Mechanisms in Multiple Sclerosis Using Gene Expression Microarrays: Treatment Effect and Cytokine-related Pathways , 2004, Clinical & developmental immunology.
[41] P. Villoslada,et al. Pharmacogenomics of Type I interferon therapy: a survey of response-modifying genes. , 2007, Cytokine & growth factor reviews.
[42] W. A. LaFramboise,et al. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing β-interferon therapy , 2007, Journal of the Neurological Sciences.
[43] Robert Gentleman,et al. Using GOstats to test gene lists for GO term association , 2007, Bioinform..
[44] Jerry Li,et al. Within the fold: assessing differential expression measures and reproducibility in microarray assays , 2002, Genome Biology.
[45] Steven Jupe,et al. A family of fatty acid binding receptors. , 2005, DNA and cell biology.
[46] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.
[47] Giulio Superti-Furga,et al. Charting protein complexes, signaling pathways, and networks in the immune system , 2006, Immunological reviews.
[48] A. Svejgaard,et al. Identification of new sensitive biomarkers for the in vivo response to interferon‐β treatment in multiple sclerosis using DNA‐array evaluation , 2009, European journal of neurology.
[49] R. Strieter,et al. CXCL10 impairs beta cell function and viability in diabetes through TLR4 signaling. , 2009, Cell metabolism.
[50] Hamid Bolouri,et al. A data integration methodology for systems biology. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[51] L. Greller,et al. Transcription-Based Prediction of Response to IFNβ Using Supervised Computational Methods , 2004, PLoS biology.
[52] Takafumi Hara,et al. Free fatty acid receptors and drug discovery. , 2008, Biological & pharmaceutical bulletin.
[53] Crispin J. Miller,et al. Cell Culture , 2010, Cell.
[54] C. Polman,et al. Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients , 2008, PloS one.
[55] George Stephanopoulos,et al. Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells , 2004, Journal of Neuroimmunology.
[56] Parvin Mousavi,et al. Genome-Wide Network Analysis Reveals the Global Properties of IFN-β Immediate Transcriptional Effects in Humans12 , 2007, The Journal of Immunology.